STOCK TITAN

REGENXBIO (RGNX) amends Schedule TO to update employee option exchange content

(Neutral)
(Neutral)
Form Type
SC TO-I/A

Rhea-AI Filing Summary

REGENXBIO Inc. amends its Schedule TO to report updates to an Exchange Offer that permits certain non-executive employees to exchange eligible outstanding stock options for replacement options under the terms of the company’s Offer to Exchange dated June 3, 2026. The amendment includes communications, FAQs, and plan documents; other Schedule TO disclosures remain unchanged.

Positive

  • None.

Negative

  • None.
Exchange Offer financial
"offer by the Company (the “Exchange Offer”) to certain non-executive employees"
An exchange offer is a proposal where a company asks investors to swap existing securities, like bonds or shares, for new ones, often with different terms or maturity dates. It matters to investors because it can affect the value of their holdings and the company's financial strategy, potentially providing benefits like better interest rates or reduced debt.
Schedule TO regulatory
"This Amendment No. 1 to Schedule TO (together with any exhibits and annexes attached hereto"
A phrase indicating that a company plans or intends to hold an event, publish information, or take an action at a specified future time, but that the timing is not guaranteed and may change. For investors it signals an expected milestone—like an earnings call, product launch, or filing—so think of it as a calendar note rather than a firm promise; timing shifts can affect trading, expectations, and planning.
Equity Incentive Plan financial
"2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.3"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Restricted Stock Unit financial
"Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Form S-8 regulatory
"Registration Statement on Form S-8 (File No. 333-288040) filed with the SEC on June 13, 2025"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What is REGENXBIO's (RGNX) Exchange Offer described in the amendment?

The Exchange Offer allows certain non-executive employees to exchange eligible outstanding stock options for replacement options under the Offer to Exchange dated June 3, 2026. The amendment updates communications, FAQs, screenshots and related exhibits to the original Schedule TO.

Which employees are eligible for the option exchange in RGNX's filing?

The filing states the Exchange Offer is made to certain non-executive employees. The amendment incorporates the Offer to Exchange and related employee communications dated June 3, 2026 and July 1, 2026 for details on eligibility and terms.

What exhibits does the Schedule TO amendment attach for RGNX?

The amendment lists the Offer to Exchange, communications from the Chief People Officer, FAQs, presentation materials, screenshots of the option exchange website, and related forms and plan documents, including references to the 2015 and 2025 Equity Incentive Plans.

Does the amendment change the company’s equity plans or award agreements?

The amendment incorporates existing plan documents by reference, including the 2015 Equity Incentive Plan and the 2025 Equity Incentive Plan and their award agreement forms; it states other Schedule TO information remains unchanged except for the listed updates.

When was this Amendment No. 1 signed for REGENXBIO (RGNX)?

The signature block shows the amendment was executed by Curran Simpson, President and Chief Executive Officer, with the date July 1, 2026. The amendment supplements the Schedule TO originally filed on June 3, 2026.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE TO

 

(Amendment No. 1)

(Rule 13a-4)

Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

 

REGENXBIO Inc.

(Name of Subject Company (Issuer) and Filing Person (Offeror))

 

Options to Purchase Common Stock, Par Value $0.0001 per share

(Title of Class of Securities)

 

75901B107

(CUSIP Number of Class of Securities)

 

Curran Simpson

President and Chief Executive Officer

REGENXBIO Inc.

9804 Medical Center Drive

Rockville, Maryland 20850

(240) 552-8181

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person)

 

With Copies to:

 

Patrick J. Christmas

Executive Vice President, Chief Strategy and Legal Officer

REGENXBIO Inc.

9804 Medical Center Drive

Rockville, Maryland 20850

(240) 552-8181

Kerry Shannon Burke

Matthew C. Franker

Covington & Burling LLP

One CityCenter

850 Tenth Street N.W.

Washington, D.C. 20001

(202) 662-6000

 

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

third party tender offer subject to Rule 14d-1.

Issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

 

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

 

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 


This Amendment No. 1 to Schedule TO (together with any exhibits and annexes attached hereto, this “Amendment No. 1”), is filed by REGENXBIO Inc., a Delaware corporation (the “Company”), and amends and supplements the Tender Offer Statement on Schedule TO filed by the Company with the Securities and Exchange Commission on June 3, 2026 (the “Schedule TO”). The Schedule TO relates to an offer by the Company (the “Exchange Offer”) to certain non-executive employees to exchange some or all of their eligible outstanding options to purchase shares of the Company’s common stock for replacement options to purchase shares of the Company’s common stock, upon the terms and subject to the conditions set forth in the Offer to Exchange Eligible Options for Replacement Options dated June 3, 2026 (the “Offer to Exchange”), included as Exhibit (a)(1)(A) to the Schedule TO and incorporated herein by reference.

This Amendment No. 1 is being made to reflect certain updates as described below. Except as otherwise set forth in this Amendment No. 1, the information set forth in the Schedule TO and the exhibits filed therewith remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 1. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO. You should read this Amendment No. 1 together with the Schedule TO and the Offer to Exchange.

Item 12. Exhibits.

 

Exhibit

Number

Description

(a)(1)(A)*

 

Offer to Exchange Eligible Options for Replacement Options, dated June 3, 2026

 

 

 

(a)(1)(B)*

 

Communication to Employees from Chief People Officer, sent on June 3, 2026

 

 

 

(a)(1)(C)*

 

Form of Announcement Email

 

 

 

(a)(1)(D)*

 

Terms of Election

 

 

 

(a)(1)(E)*

 

Form of Confirmation Email

 

 

 

(a)(1)(F)*

 

Form of Reminder Email

 

 

 

(a)(1)(G)*

 

Screenshots of Option Exchange Website

 

 

 

(a)(1)(H)*

 

Option Exchange Frequently Asked Questions

 

 

 

(a)(1)(I)*

 

Employee Presentation

 

 

 

(a)(1)(J)

 

Communication to Eligible Employees from Chief People Officer, sent on July 1, 2026

 

 

 

(b)

 

Not applicable

 

 

 

(d)(1)*

 

2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form S-1/A (File No. 333-206430) filed with the SEC on September 15, 2015)

 

 

 

(d)(2)*

 

Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 of the Annual Report on Form 10-K (File No. 001-37553) filed with the SEC on March 1, 2021)

 

 

 

(d)(3)*

 

Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of the Annual Report on Form 10-K (File No. 001-37553) filed with the SEC on March 1, 2021)

 

 

 

(d)(4)*

 

REGENXBIO Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 of the Registration Statement on Form S-8 (File No. 333-288040) filed with the SEC on June 13, 2025)

 

 

 

(d)(5)*

 

Form of Restricted Stock Unit Award Agreement for the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q (File No. 001-37553) filed with the SEC on August 7, 2025)

 

 

 

(d)(6)*

 

Form of Stock Option Award Agreement for the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 of the Quarterly Report on Form 10-Q (File No. 001-37553) filed with the SEC on August 7, 2025)

 

 

 

(d)(7)*

 

2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 of the Registration Statement on Form S-1/A (File No. 333-206430) filed with the SEC on September 8, 2015)

 

 

 

(g)

 

Not applicable

 

 

 

(h)

 

Not applicable

 

 

 

107*

 

Filing Fee Table

 

* Previously filed.

 


SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

 

REGENXBIO INC.

 

 

 

 

Date:

July 1, 2026

By:

/s/ Curran Simpson

 

 

 

President and Chief Executive Officer